0001415889-23-009136.txt : 20230602 0001415889-23-009136.hdr.sgml : 20230602 20230602200040 ACCESSION NUMBER: 0001415889-23-009136 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230531 FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reumuth Mary CENTRAL INDEX KEY: 0001710969 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38150 FILM NUMBER: 23990920 MAIL ADDRESS: STREET 1: 100 BEAVER STREET STREET 2: SUITE 201 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kala Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001479419 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270604595 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 BUSINESS PHONE: 781-996-5252 MAIL ADDRESS: STREET 1: 1167 MASSACHUSETTS AVENUE CITY: ARLINGTON STATE: MA ZIP: 02476 4 1 form4-06022023_080614.xml X0407 4 2023-05-31 0001479419 Kala Pharmaceuticals, Inc. KALA 0001710969 Reumuth Mary C/O KALA PHARMACEUTICALS, INC. 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 false true false false CHIEF FINANCIAL OFFICER 0 Common Stock 2023-05-31 4 A 0 14736 A 26619 D Stock Option (right to buy) 167 2023-05-31 4 D 0 1841 D 2025-06-17 Common Stock 1841 0 D Stock Option (right to buy) 750 2023-05-31 4 D 0 578 D 2027-07-18 Common Stock 578 0 D Stock Option (right to buy) 643 2023-05-31 4 D 0 1399 D 2028-02-06 Common Stock 1399 0 D Stock Option (right to buy) 259.50 2023-05-31 4 D 0 2999 D 2029-01-01 Common Stock 2999 0 D Stock Option (right to buy) 192 2023-05-31 4 D 0 2399 D 2030-01-01 Common Stock 2399 0 D Stock Option (right to buy) 343 2023-05-31 4 D 0 1813 D 2031-01-03 Common Stock 1813 0 D Stock Option (right to buy) 68.50 2023-05-31 4 D 0 3059 D 2032-01-03 Common Stock 3059 0 D Stock Option (right to buy) 68.50 2023-05-31 4 D 0 648 D 2032-01-03 Common Stock 648 0 D On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. Includes 24,412 unvested RSUs. The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. The canceled option was granted on June 17, 2016 and provided for vesting over four years with 1/48th of the shares underlying the option vested on April 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter. The canceled option was granted on July 19, 2017 and provided for vesting over four years with 1/48th of the shares underlying the option vested on August 31, 2017 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter. The canceled option was granted on February 7, 2018 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. The canceled option was granted on January 3, 2022 and provided for the purchase of up to 1,620 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 432 shares had vested, options to purchase 864 shares had been forfeited and options to purchase up to 324 shares were unvested assuming maximum level of achievement (options to purchase 216 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program. /s/ Eric Trachtenberg, Attorney-in-Fact 2023-06-02